Physician profile
Rami Abboud
NPI 1487854972
$6,669.51
in general payments reported to CMS, 2019-2025
36 companies · $800 in 2025
The $800 reported for 2025 was more than what a typical Pulmonary Disease provider received nationally (typical 2025 total: $500).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $651 · 2020: $633 · 2021: $450 · 2022: $1,051 · 2023: $1,453 · 2024: $1,633 · 2025: $800.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $3,221 · Travel and Lodging: $664.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $3,221.33 |
| Travel and Lodging | $663.96 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Inspire Medical Systems, INC. | $1,829.42 | 2020-2025 | Inspire |
| Glaxosmithkline, LLC. | $901.38 | 2019-2024 | Nucala, Trelegy Ellipta |
| Astrazeneca Pharmaceuticals Lp | $577.13 | 2019-2024 | Fasenra, Breztri, Symbicort |
| Boehringer Ingelheim Pharmaceuticals, INC. | $542.75 | 2019-2023 | Spiriva Respimat, Ofev, Stiolto Respimat |
| Genzyme Corporation | $506.52 | 2019-2024 | |
| Electromed, INC. | $392.32 | 2024-2025 | Smartvest |
| Actelion Pharmaceuticals US, INC. | $313.57 | 2019-2023 | Opsumit |
| Grifols USA, LLC | $156.50 | 2022-2025 | Prolastin-C Liquid |
| Mylan Specialty L.P. | $150.17 | 2019-2023 | Yupelri |
| Baxter Healthcare | $146.66 | 2022-2024 | Hillrom - Vest System Model 105 Home Care |
| United Therapeutics Corporation | $124.74 | 2021-2025 | |
| Verona Pharma, INC. | $120.79 | 2025 | Ohtuvayre |
| Zoll Services LLC (A/K/A Zoll Lifecor Corp) | $105.13 | 2023-2024 | Lifevest |
| Regeneron Healthcare Solutions, INC. | $102.26 | 2022-2023 | Dupixent |
| Harmony Biosciences LLC | $84.40 | 2020-2023 | Wakix |
Show all 36 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Teva Pharmaceuticals USA, INC. | $73.86 | 2021-2023 | Airduo Digihaler |
| Amgen INC. | $68.89 | 2022-2023 | Tezspire |
| Jazz Pharmaceuticals INC. | $68.06 | 2019-2021 | |
| Medtronic, INC. | $46.13 | 2021 | |
| Insmed, INC. | $38.13 | 2019 | |
| Sunovion Pharmaceuticals INC. | $37.06 | 2021 | |
| Itamar Medical INC | $36.19 | 2024 | Watchpatone |
| Novartis Pharmaceuticals Corporation | $31.89 | 2019-2021 | |
| Pulmonx Corporation | $25.30 | 2020 | |
| Astellas Pharma US INC | $24.53 | 2022 | |
| Bayer Healthcare Pharmaceuticals INC. | $22.95 | 2023 | |
| Genentech USA, INC. | $21.44 | 2019 | |
| Eisai INC. | $16.27 | 2020 | |
| Portola Pharmaceuticals, LLC | $15.53 | 2019 | |
| Otsuka America Pharmaceutical, INC. | $15.45 | 2019 | |
| Novo Nordisk INC | $15.42 | 2022 | |
| Pfizer INC. | $12.34 | 2019 | |
| Shire North American Group INC | $11.92 | 2019 | |
| Nabriva Therapeutics, Plc | $11.85 | 2020 | |
| Mayne Pharma Commercial LLC | $11.29 | 2019 | |
| Janssen Pharmaceuticals, INC | $11.27 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Rami Abboud listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.